TMPRSS2 and prostate carcinoma: GOLM1, CD24, PSCA, and the gene fusion TMPRSS2-ERG were selected as overexpressed mRNAs in prostate cancer, whereas ANXA3 and SLC45A3 were selected as underexpressed mRNAs in prostate cancer for evaluation.